Flibanserin clinical trials
Also written Addyi.
How each study uses flibanserin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 18 Aug 2015 · ADDYI · NDA 022526 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2010 (5)
| Year | Studies |
|---|---|
| 2006 | 4 |
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 5 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 4
Sprout Pharmaceuticals, Inc (11) · Andrew McDonald (1) · Genuine Research Center, Egypt (1) · Boehringer Ingelheim (1) · Mohit Khera (1) · University of Chicago (1) · San Diego Sexual Medicine (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses flibanserin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- Flibanserin in Men Receiving Androgen Suppression for Prostate CancerCompletedPhase 2Andrew McDonaldNCT04743934Written as Flibanserin 100 MGHow we know
- Hypoactive Sexual Desire Disorder in MalesTerminatedPhase 2Mohit KheraNCT04002661Written as FlibanserinHow we know
- Effects of Flibanserin on the Pre- and Post-menopausal Female BrainTerminatedNot applicableUniversity of ChicagoNCT02770768Written as FlibanserinHow we know
- Flibanserin (Addyi®) vs. Flibanserin and Sex TherapyTerminatedPhase 4San Diego Sexual MedicineNCT02714049Written as flibanserinHow we know
- Bioequivalence Study of Flibanserin From AphroFemine 100 mg F.C.T (Bio Med for Pharmaceuticals Industries (BIOMED), Egypt) Versus Addyi 100 mg Tablets (Sprout Pharmaceuticals, Inc., USA)CompletedPhase 1Genuine Research Center, EgyptNCT04494191Written as Flibanserin 100Mg TabHow we know
- 12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and DistressTerminatedPhase 3Sprout Pharmaceuticals, IncNCT01040208Written as flibanserin 50 mg to 100 mg qhsHow we know
- 24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire DisorderCompletedPhase 3Sprout Pharmaceuticals, IncNCT00360529Written as flibanserinHow we know
- Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire DisorderCompletedPhase 3Sprout Pharmaceuticals, IncNCT00360555Written as flibanserinHow we know
- 6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NACompletedPhase 3Sprout Pharmaceuticals, IncNCT00360243Written as flibanserinHow we know
- Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North AmericaTerminatedPhase 3Sprout Pharmaceuticals, IncNCT01057901Written as FlibanserinHow we know
- A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).TerminatedPhase 3Sprout Pharmaceuticals, IncNCT00441558Written as FlibanserinHow we know
- Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal WomenCompletedPhase 3Sprout Pharmaceuticals, IncNCT00996372Written as flibanserinHow we know
- Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)CompletedPhase 1Sprout Pharmaceuticals, IncNCT01188603Written as flibanserin 100 mg dose every eveningHow we know
- Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire DisorderCompletedPhase 3Sprout Pharmaceuticals, IncNCT00996164Written as FlibanserinHow we know
- A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire DisorderTerminatedPhase 3Sprout Pharmaceuticals, IncNCT01103362Written as flibanserinHow we know
- Flibanserin Randomized Withdrawal Trial in Pre-menopausal WomenCompletedPhase 3Sprout Pharmaceuticals, IncNCT00277914Written as FlibanserinHow we know
- to Evaluate Effect of Multi Doses Flibans 100 mg Film-c Tablets on Single Dose PK of Digoxin 0.5 mg, Healthy VolunteersCompletedPhase 1Boehringer IngelheimNCT01134965Written as Flibanserin plus DigoxinHow we know
Codes
What other systems call flibanserin · ClinicalTrials.gg INT003890
- MeSH (NLM) C098107flibanserinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 37JK4STR6ZFLIBANSERINConfirmed FDA, NLM, Wikidata
- RxNorm 1665509Confirmed FDA, Wikidata
- Wikidata Q415996flibanserinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C80769FlibanserinOne source FDA
- DrugBank DB04908One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C098107 | flibanserin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 37JK4STR6Z | FLIBANSERIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1665509 | — | Confirmed FDA, Wikidata |
| Wikidata | Q415996 | flibanserin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C80769 | Flibanserin | One source FDA |
| DrugBank | DB04908 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.